Tinjauan Klinis CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy)
DOI:
https://doi.org/10.55175/cdk.v48i8.108Kata Kunci:
penyakit herediter, CADASILAbstrak
CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) adalah penyakit herediter langka dengan prevalensi 4,14 per 100.000. Penyakit ini disebabkan mutasi gen Notch 3 pada kromosom 19. Manifestasi klinisnya bervariasi dengan onset gejala awal migrain dengan aura. Pada tahap lanjut akan dijumpai lesi infark multipel di area subkortikal. Pasien juga dapat mengalami gangguan psikiatri dan neurobehaviour. Tidak ada terapi kausal, dapat diberikan terapi simptomatik.
CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) is a rare hereditary disease with a prevalence of 4.14 per 100,000. The disease is caused by a mutation of the Notch 3 gene on chromosome 19. The clinical manifestations vary with the onset of initial symptoms is migraine with aura. In advanced stages, there will be multiple infarct lesions in the subcortical area. Patients may also experience psychiatric and neurobehavioral disorders. There is no causal therapy, only symptomatic therapy.
Unduhan
Referensi
Choudhary S, McLeod M, Torchia D, Romanelli P. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). J Clin Aesthet Dermatol. 2013;6(3):29-33.
Andre C. Cadasil: Pathogenesis, clinical and radiological findings and treatment. Arq Neuropsiquiatr. 2010;68(2):287-99.
Chabriat H, Juotel A, Lasserve ET, Bousser MG. Cadasil: Yesterday, today, tomorrow. Eur J Neurol. 2020;0:1-8.
Razvi SS, Davidson R, Bone I, Muir KW. The prevalence of cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) in the West of Scotland. J Neurol Neurosurg Psychiatry. 2005;76:739-41.
Markus HS, Martin RJ, Simpson MA, Dong YB, Ali N, Crosby H, et al. Diagnostic strategies in CADASIL. Neurology 2002;59:1134 - 8.
Di Donato I, Bianchi S, De Stefano N, Dichgans M, Dotti MT, Duering M, et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) as a model of small vessel disease: Update on clinical, diagnostic, and management aspects. BMC medicine. 2017;15:41.
Guey S, Mawet J, Herve D, Duering M, Godin O, Jouvent E, et al. Prevalence and charecteristics of migraine in CADASIL. Cephalalgia 2016; 36:1038-47.
Tan RY, Markus HS. Cadasil: Migraine, encephalopathy, stroke and their inter-relationship. PLoS One. 2016;11:e0157613.
Drazky AM, Tan RYY, Tay J, Traylor M, Das T, Markus HS. Encephalopathy in a large cohort of British cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy patients. Stroke 2019;50:283-90.
Valenti R, Poggesi A, Pescini A, Inzitari D, Pantoni L. Psychiatric disturbances in CADASIL: A brief review. Acta Neurol Scan. 2008;118:291-5.
Opherk C, Peters N, Herzog J, Luedtke R, Dichgans M. Long term prognosis and causes of death in CADASIL: A retrospective study in 411 patients. Brain.2004;127:2533-9.
Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. CADASIL. Lancet Neurol. 2009;8:643-53.
Donnini I, Nannucci S, Valenti R, Pescini F, Bianchi S, Inzitari D, et al. Acetazolamide for the prophylaxis of migraine in CADASIL: A preliminary experience. J Headache Pain. 2012;13(4):299-302.
Martikainen MH, Roine S. Rapid improvement of a complex migrainous episode with sodium valproat in a patient with CADASIL. J Headache Pain 2012;13:95-7.
Keverne JS, Low WC, Ziabreva I, Court JA, Oakley AE, Kalaria RN. Cholinergic neuronal deficits in CADASIL. Stroke 2007;38(1):188-91.
Rinocci V, Nannuci S, Valenti R, Donnini I, Bianchi S, Pescini F, et al. Cerebral hemorrhages in CADASIL: Report of four cases and a brief review. J Neurol Sci. 2013;330:45-51.
Dichgans M, Markus HS, Salloway S, Verkkoniemi A, Moline M, Wang Q, et al. Donepezil on patients with subcortical vascular cognitive impairment: A randomised double-blind trial in CADASIL. Lancet Neurol. 2008;7:310-8.
Joshi S, Yau W, Kermode A. CADASIL: Mimicking multiple sclerosis: The importance of clinical and MRI red flags. J Clin Neurosci. 2017;35:75-7.
Perneczky R, Tene O, Atterns J, Giannakopolous P, Ikram MA, Federico A, et al. Is the time ripe for new diagnostic criteria of cognitive impairment due to cerebrovascular disease? Consensus report of the international Congress on Vascular Dementia Working Group. BMC Med. 2016;14 :162.
Bersano A, Bedini G, Oskam J, Mariotti C, Taroni R, Baratta S, et al. CADASIL: Treatment and management options. Curr Treat Options Neurol. 2017;19:31.
Park S, Park B, Koh MK, Joo YH. Case report: Bipolar disorder as the first manifestation of CADASIL. BMC Psychiatry. 2014;14:175.
Ho CS, Mondry A. CADASIL presenting as schizophreniform organic psychosis. Gen Hosp Psychiatry. 2015;37:273.11–3.
Low WC, Junna M, Borjesson-Hanson A, Morris CM, Moss TH, Stevens DL, et al. Hereditary multi-infarct dementia of the Swedish type is a novel disorder different from NOTCH3 causing CADASIL. Brain. 2007; 130:357-67.
Buffon F, Porcher R, Hernandez K, Kurtz A, Pointeau S, Vahedi K, et al. Cognitive profile in CADASIL. J Neurol Neurosurg Psychiatry. 2006;77:155-80.
Olesen J (Chairman Commitee). The International Classification of Headache Disorders, 3rd ed. Headache Classification Committee of the International Headache Society (IHS). Cephalalgia 2018;38(1):1-211.
Cleves C, Friedman NR, Rothner D, Hussain M. Genetically confirmed CADASIL in a pediatric patient. Pediatrics 2010;126(6):1603-7
Rego JL, Franca S, Ribeiro L, Silva IS. Rare case of CADASIL disease associated to factor V Leiden mutation in pregnancy. Acta Obstet Ginecol Port. 2014;8(3):304-6.
Aljamal A. CADASIL subcortical dementia – a case report. Case Reports [Internet]. 2019; 33. Available from: https://scholarlycommons.henryford.com/merf2019caserpt/33
Holtmannspötter M, Peters N, Opherk C, Martin D, Herzog J, Brückmann H, et al. Diffusion magnetic resonance histograms as a surrogate marker and predictor of disease progression in CADASIL: A two-year follow-up study. Stroke 2005;36:2559–65.
Viswanathan A, Guichard JP, Gschwendtner A, Buffon F, Cumurcuic R, Boutron C, et al. Blood pressure and haemoglobin A1c are associated with microhaemorrhage in CADASIL: a two-centre cohort study. Brain 2006;129:2375–8.
Peters N, Holtmannspötter M, Opherk C, Gschwendtner A, Herzog J, Sämann P, et al. Brain volume changes in CADASIL: A serial MRI study in pure subcortical ischemic vascular disease. Neurology 2006;66:1517–22.
Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet 2001;358(9294):1668–75.
Tfelt-Hansen P, Saxena PR, Dahlöf C, Pascual J, Láinez M, Henry P, et al. Ergotamine in the acute treatment of migraine: A review and European consensus. Brain 2000;123:9–18.
Singhal S, Bevan S, Barrick T, Rich P, Markus HS. The influence of genetic and cardiovascular risk factors on the CADASIL phenotype. Brain 2004;127:2031–8.
Anamart C, Songsaeng D, Chanprasert S. A large number of cerebral microbleeds in CADASIL patients presenting with recurrent seizures: A case report. BMC Neurol.2019;19: 106.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2021 Cermin Dunia Kedokteran
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
